Richard Dilorio Sells 5,398 Shares of InfuSystem Holdings, Inc. (NYSE:INFU) Stock

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 5,398 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $8.87, for a total transaction of $47,880.26. Following the completion of the sale, the chief executive officer now directly owns 416,659 shares of the company’s stock, valued at approximately $3,695,765.33. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Richard Dilorio also recently made the following trade(s):

• On Monday, November 25th, Richard Dilorio sold 20,000 shares of InfuSystem stock. The shares were sold at an average price of $9.32, for a total transaction of $186,400.00.

InfuSystem Stock Performance

Shares of NYSE:INFU opened at $8.86 on Friday. The company has a 50-day simple moving average of $7.29. InfuSystem Holdings, Inc. has a one year low of $5.74 and a one year high of $10.99. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $188.36 million, a PE ratio of 147.67 and a beta of 1.45.

Institutional Investors Weigh In On InfuSystem

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets raised its holdings in shares of InfuSystem by 66.4% in the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after buying an additional 1,626 shares during the last quarter. Williams & Novak LLC acquired a new position in shares of InfuSystem during the third quarter worth about $70,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of InfuSystem during the third quarter worth about $87,000. Rhumbline Advisers increased its stake in shares of InfuSystem by 13.8% during the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock worth $121,000 after acquiring an additional 2,145 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of InfuSystem during the second quarter worth about $131,000. 71.13% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

INFU has been the subject of a number of research reports. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th. B. Riley initiated coverage on shares of InfuSystem in a research report on Thursday, September 26th. They issued a “buy” rating and a $13.00 price target for the company.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.